Results 31 to 40 of about 321,589 (402)

A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy

Circulation, 2020
Supplemental Digital Content is available in the text. Background: Hypertrophic cardiomyopathy is the leading cause of sudden cardiac death (SCD) in children and young adults.
A. Miron, M. Lafreniere-Roula, Chun-Po Steve Fan, K. Armstrong, A. Dragulescu, Tanya Papaz, C. Manlhiot, B. Kaufman, R. Butts, L. Gardin, E. Stephenson, Taylor S. Howard, P. Aziz, S. Balaji, Virginie Beauséjour Ladouceur, L. Benson, S. Colan, J. Godown, H. Henderson, J. Ingles, A. Jeewa, J. Jefferies, A. Lal, J. Mathew, E. Jean-St-Michel, M. Michels, S. Nakano, I. Olivotto, J. Parent, A. Pereira, C. Semsarian, R. Whitehill, S. Wittekind, M. Russell, J. Conway, M. Richmond, C. Villa, R. Weintraub, J. Rossano, P. Kantor, Carolyn Y. Ho, S. Mital   +41 more
semanticscholar   +1 more source

A next-generation sequencing approach to identify gene mutations in early-and late-onset hypertrophic cardiomyopathy patients of an Italian cohort [PDF]

, 2016
Sequencing of sarcomere protein genes in patients fulfilling the clinical diagnostic criteria for hypertrophic cardiomyopathy (HCM) identifies a disease-causing mutation in 35% to 60% of cases.
Autore, Camillo, Bozzao, Cristina, Chessa, Luciana, Francia, Pietro, Germani, Aldo, Musumeci, Maria Beatrice, Pagannone, Erika, Pennacchini, Ermelinda, Piane, Maria, Rubattu, Speranza, Savio, Camilla, Volpe, Massimo   +11 more
core   +1 more source

An overview of the current genetic and phenotypical selection strategies to reduce the prevalence of feline hypertrophic cardiomyopathy = Een overzicht van de huidige genetische en fenotypische selectiestrategieën tegen hypertrofe cardiomyopathie bij de kat [PDF]

, 2020
Hypertrophic cardiomyopathy (HCM) is a common and potentially lethal heart disease in cats. To reduce its prevalence, breeding cats are frequently screened on the basis of their phenotype or genotype.
Broeckx, Bart, Peelman, Luc, Schipper, Tom, Smets, Pascale   +3 more
core   +1 more source

Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
BackgroundThe subcutaneous implantable cardioverter defibrillator (S‐ICD) has been developed to avert risks associated with transvenous defibrillator leads. The technology is attractive for younger patients, such as those with hypertrophic cardiomyopathy
Jonathan Weinstock, Yousef H. Bader, Martin S. Maron, Ethan J. Rowin, Mark S. Link   +4 more
doaj   +1 more source

Automated segmentation of left ventricular myocardium using cascading convolutional neural networks based on echocardiography

AIP Advances, 2021
Quickly and accurately segmenting the left ventricular (LV) myocardium from ultrasound images and measuring the thickness of the interventricular septum and LV wall play an important role in hypertrophic cardiomyopathy.
Shenghan Ren, Yongbing Wang, Rui Hu, Lei Zuo, Liwen Liu, Heng Zhao   +5 more
doaj   +1 more source

Acute Left Ventricular Ballooning: Tools to Differentiate Hypertrophic Cardiomyopathy with Outflow Obstruction from Neurohumoral Takotsubo Syndrome

Reviews in Cardiovascular Medicine, 2023
Despite considerable interest in the syndrome of acute left ventricular (LV) ballooning, its pathophysiology has remained ill-defined. In this review, we explore observational data describing two etiologies of acute LV ballooning: neurohumoral classic ...
Arushi Singh, Louai Razzouk, Daniele Massera, Mark V. Sherrid   +3 more
doaj   +1 more source

Pattern and degree of left ventricular remodeling following a tailored surgical approach for hypertrophic obstructive cardiomyopathy. [PDF]

, 2012
Background The role of a tailored surgical approach for hypertrophic cardiomyopathy (HCM) on regional ventricular remodelling remains unknown. The aims of this study were to evaluate the pattern, extent and functional impact of regional ventricular ...
Cecchi, F, El Guindy, A, El-Hamamsy, I, Lekadir, K, Merrifield, R, Olivotto, I, Rega, L, Yacoub, MH, Yang, G   +8 more
core   +2 more sources

Hypertrophic cardiomyopathy: the future of treatment

European Journal of Heart Failure, 2020
Hypertrophic cardiomyopathy (HCM) is a heterogeneous genetic disorder most often caused by sarcomeric mutations resulting in left ventricular hypertrophy, fibrosis, hypercontractility, and reduced compliance.
C. V. Tuohy, S. Kaul, Howard K Song, B. Nazer, S. Heitner   +4 more
semanticscholar   +1 more source

Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction

Circulation, 2020
Supplemental Digital Content is available in the text. Background: The term “end stage” has been used to describe hypertrophic cardiomyopathy (HCM) with left ventricular systolic dysfunction (LVSD), defined as occurring when left ventricular ejection ...
Peter Marstrand, Larry Han, S. Day, I. Olivotto, E. Ashley, M. Michels, A. Pereira, S. Wittekind, A. Helms, S. Saberi, D. Jacoby, J. Ware, S. Colan, C. Semsarian, J. Ingles, N. Lakdawala, Carolyn Y. Ho   +16 more
semanticscholar   +1 more source

Prediction of sarcomere mutations in subclinical hypertrophic cardiomyopathy. [PDF]

, 2014
BACKGROUND: Sarcomere protein mutations in hypertrophic cardiomyopathy induce subtle cardiac structural changes before the development of left ventricular hypertrophy (LVH).
Bassett, P, Bluemke, DA, Canter, CE, Captur, G, Day, SM, Elliott, PM, Esteban, MT, Ferreira, VM, Finocchiaro, G, Ho, CY, Li, C, Lopes, LR, McKenna, WJ, Mohun, TJ, Moon, JC, Muthurangu, V, Patel, V, Seidman, CE, Sherrid, MV   +18 more
core   +1 more source